• 1
    Huggins C, Hodges CV. Studies on prostate cancer. I. The effects of castration, of estrogen and androgen injection on serum phosphatises in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 2937
  • 2
    Charles B. Huggins – nobel lecture. 2012. Available at: Accessed 10 May 2012
  • 3
    Mottet N, Bellmunt J, Bolla M et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing and castration-resistant prostate cancer. Eur Urol 2011; 59: 57283
  • 4
    Horwich A, Parker C. Kataja V on behalf of the ESMO guidelines working group. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (Suppl. 4): 768
  • 5
    Eisenberger MA, Blumenstein BA, Crawford ED et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 103642
  • 6
    Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 444754
  • 7
    Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration resistant prostate cancer. Cancer Res 2008; 68: 640715
  • 8
    Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 166571
  • 9
    Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisosn or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end-points. J Clin Oncol 1996; 14: 175664
  • 10
    Petrylak DP, Tangen CM, Hussein MHA et al. Docetaxel and estrasmustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 151320
  • 11
    Tannock IF, de Wit R, Berry WR et al.; for TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 150212
  • 12
    De Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet 2010; 376: 114754
  • 13
    Sartor O, Oudard S, Ozguroglu M et al. Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial. J Clin Oncol 2011; 29 (Suppl. 15): [abstract] 4525
  • 14
    Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004 4: 25365
  • 15
    Kuroda K, Liu H, Kim S et al. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. Prostate 2009; 69: 157985
  • 16
    Gan L, Chen S, Wang Y et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009; 69: 838694
  • 17
    Zhu M-L, Horbinski CM, Garzotto M et al. Tubulin-targeting chemotherapy impairs receptor activity in prostate cancer. Cancer Res 2010; 70: 79928002
  • 18
    De Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 19952005
  • 19
    Scher HI, Fizazi K, Saad F et al. Effect of MDV3100, an androgen receptor signaling inhibitor, on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J Clin Oncol 2012; 30 (Suppl. 5): [abstract] LBA1
  • 20
    Scher HI, Beer TM, Higano CS et al. Antitumor activity of MDV3100 in castration-resistant prostate cancer. Lancet 2010; 375: 143746
  • 21
    Mezinski J, Attard G, Zivi A et al. Evaluating the antitumor activity of docetaxel following treatment with abiraterone acetate and steroids: evidence for cross-resistance. Crit Rev Oncol Hematol 2011; 78 (Suppl. 1): S23. (Abstract 31)
  • 22
    Tang Y, Khan MA, Goloubeva O et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 2006; 12: 16974
  • 23
    Osborne CK, Kitten L, Arteaga CL et al. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by anti-estrogens. J Clin Oncol 1989; 7: 71017
  • 24
    Albain KS, Barlow WE, Ravdin PM et al. Adjuvant chemotherapy and timing of tamoxifen in post-menopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomized controlled trial. Lancet 2009; 374: 205563
  • 25
    Attard G, Richards J, De Bono JS. New strategies in metastatic prostate cancer: targeting the androgen receptor signalling pathway. Clin Cancer Res 2011; 17: 164957